Could a common diabetes drug ease muscle problems in Steinert's disease?

NCT ID NCT05532813

Recruiting now Symptom relief Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial is testing whether metformin, a common diabetes drug, can improve muscle function in adults with myotonic dystrophy type 1 (Steinert's disease). The study will enroll 142 participants who will receive either metformin or a placebo for 6 months. Researchers will measure changes in motor function, strength, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Metformin
What this could lead to: If it works, this could point toward a treatment to improve muscle function and quality of life in people with myotonic dystrophy type 1.
What could go wrong: This is a phase 3 trial, but metformin is already used for diabetes; its benefit for muscle function in this disease is unproven. Side effects like digestive issues or rare lactic acidosis are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METFORMIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myotonic dystrophy myotonic dystrophy type 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METFORMIN MYOTONIC DYSTROPHY 1 STEINERT'S DISEASE

Contacts and locations

Locations

Neurology Department, Raymond-Poincaré hospital - APHP
RECRUITING

Garches, 92380, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.